Related Experiment Video
Updated: Dec 29, 2025
06:18
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
Published on: August 18, 2023
3.5K
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials
Seshu Tyagarajan1, Tom Spencer1, Jonathan Smith1
1Novartis Pharmaceuticals, East Hanover, NJ 07936, USA.
Molecular Therapy. Methods & Clinical Development
|January 29, 2020
Summary
Continuous process improvements have optimized tisagenlecleucel (CAR-T cell therapy) manufacturing for global demand. These enhancements ensure high product quality and increased manufacturing success rates for B-ALL and DLBCL patients.
Area of Science:
- Cellular immunotherapy
- Biopharmaceutical manufacturing
- Oncology
Background:
- Tisagenlecleucel is an approved CD19-CAR-T cell therapy for pediatric B-ALL and adult DLBCL.
- Initial manufacturing technology was developed academically and scaled for global clinical trials.
- Successful use in over 50 centers across 12 countries highlights the need for robust manufacturing.
Purpose of the Study:
- To describe continuous process improvements in tisagenlecleucel manufacturing.
- To detail efforts to meet global demand while maintaining and enhancing product quality.
- To address logistical challenges and patient material variability in multicenter trials.
Main Methods:
- Continuous evaluation of manufacturing processes based on global clinical trial data.
- Implementation of process enhancements to address scalability and material variability.
- Validation and optimization of manufacturing technology across centralized facilities.
Main Results:
- Significant improvements in manufacturing capacity, process robustness, and success rates.
- Enhanced product quality and reduced throughput times achieved.
- Adaptations successfully managed logistical challenges and patient cell variability.
Conclusions:
- A consistent and robust commercial manufacturing process for tisagenlecleucel has been established.
- Continuous improvement based on trial experience led to better manufacturing outcomes.
- Optimized manufacturing supports broader patient access to this CAR-T therapy.
